.jpg)
Feb 12, 2019
Aravax to Present PVX108 Phase 1 Clinical Trial Results at AAAAI 2019 Annual Meeting
February 13, 2019, MELBOURNE, Australia – Aravax, a clinical stage biotechnology company focused on developing the first safe and rapidly...
May 1, 2018
Aravax receives $1.9 million investment tranche from the Medical Research Commercialisation Fund
2 May 2018, Melbourne, Victoria – Aravax has received an additional investment of $1.9M from the Australian Medical Research...
Jan 29, 2018
Collaborator of Aravax, the Benaroya Research Institute, receives $5 million grant
29th January 2018, Seattle, United States of America –The Benaroya Research Institute in Seattle announced receipt of National Institute...
Jan 13, 2018
Aravax presents encouraging preliminary Phase I safety data at the first Gordon Research Conference
13th January 2018, California, United States of America – Australian biotechnology company Aravax presented preliminary data from the...
Jan 9, 2018
Aravax forms Scientific Advisory Board
9th January 2018, California, United States of America – Aravax, an Australian biotechnology company revolutionising peanut allergy...
Nov 17, 2017
Aravax forms research collaboration with Stanford University
17th November 2017 – Aravax today signed a collaborative agreement with Stanford University in California. The Stanford research group,...